Publications scientifiques en 2020

Depuis le 15/03/2024

  1. Polypharmacy: A general review of definitions, descriptions and determinants.
    Guillot J, Maumus-Robert S, Bezin J.
    Therapie. 2020
  2. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports and disproportionality analyses in Vigibase®.
    Perino J, Mottal N, Bohbot Y, Servant V, Berroneau A, Poustis P, Fenaux P, Laribi K, Charbonnier A, Bilion E, Calmettes C, Bégaud B, Pigneux A, Milpied N, Miremont-Salamé G, Théophile H, Dimicoli-Salazar S.
    Br J Clin Pharmacol. 2020
  3. Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
    Moore N.
    Drug Saf. 2020
  4. Risk of Intracranial Aneurysm and Dissection and Fluoroquinolone Use: A Case-Time-Control Study.
    Maumus-Robert S, Debette S, Bérard X, Mansiaux Y, Tubert-Bitter P, Pariente A.
    Stroke. 2020
  5. Are standard dosing regimens of Amikacin suitable in Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy? A population pharmacokinetic study.
    Carrié C, Delzor F, Roure S, Dubuisson V, Petit L, Molimard M, Breilh D, Biais M.
    Antimicrob Agents Chemother. 2020
  6. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T, Pariente A, Miremont-Salamé G, Grandvuillemin A, Micallef J, Chouchana L, Benkebil M, Théophile H; French Network of Pharmacovigilance Centres.
    Drug Saf. 2020
  7. Toxicological screening reveals Toxic Epidermal Necrolysis likely carbamazepine-induced rather than idiopathic.
    Toussaint C, Sanchez-Pena P, Titier K, Castaing N, Molimard M, Milpied B.
    J Allergy Clin Immunol Pract. 2020
  8. Augmentation des complications sanitaires graves lors de l’usage non-médical du protoxyde d’azote en France.
    Association française des centres d’addictovigilance, Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P.
    Therapie. 2020
  9. Warning on increased serious health complications related to non-medical use of nitrous oxide.
    French Association of Addictovigilance Centres, Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P.
    Therapie. 2020
  10. Identifying Drugs Inducing Prematurity by Mining Claims Data with High-Dimensional Confounder Score Strategies.
    Demailly R, Escolano S, Haramburu F, Tubert-Bitter P, Ahmed I.
    Drug Saf. 2020
  11. Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies?
    Devillier P, Demoly P, Molimard M.
    Expert Rev Respir Med. 2020
  12. Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project.
    Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz-Perroteau C.
    Pharmacoepidemiol Drug Saf. 2020
  13. Death related to nicotine replacement therapy: A case report.
    Tjoncke JA, Goncalves R, Castaing N, Molimard M, Tovagliaro F, Titier K.
    Forensic Sci Int. 2020
  14. Primary Care of Opioid use Disorder: The End of "the French Model"?
    Dupouy J, Maumus-Robert S, Mansiaux Y, Pariente A, Lapeyre-Mestre M.
    Eur Addict Res. 2020
  15. Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction.
    Raschi E, Salvo F, La Placa M, Poluzzi E, De Ponti F.
    J Eur Acad Dermatol Venereol. 2020
  16. The 2019 Global Initiative for Asthma report: Evidence-based or evidence-biased medicine?
    Girodet PO, Molimard M.
    Therapie. 2020
  17. The effect of the Music Day event on community drug use.
    Devault DA, Peyré A, Jaupitre O, Daveluy A, Karolak S.
    Forensic Sci Int. 2020
  18. Dolutegravir and neural tube defects: a new insight.
    Chouchana L, Pariente A, Pannier E, Tsatsaris V, Treluyer JM.
    Lancet Infect Dis. 2020
  19. Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice.
    Joly F, Oudard S, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Rouyer M, Moore N.
    Clin Genitourin Cancer. 2020
  20. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).
    Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F.
    Cancers (Basel). 2020
  21. Chloroquine for COVID-19 Infection.
    Moore N.
    Drug Saf. 2020
  22. Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review.
    Arlegui H, Nachbaur G, Praet N, Bégaud B.
    Open Forum Infect Dis. 2020
  23. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
    Pariente A, Labat V, Mansiaux Y, Salvo F, Bégaud B, Raschi E, Faillie JL, Létinier L, Bezin J.
    Drug Saf. 2020
  24. Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial.
    Bonnet F, Bénard A, Poulizac P, Afonso M, Maillard A, Salvo F, Berdaï D, Salles N, Rousselot N, Marchi S, Hayes N, Joseph JP.
    Trials. 2020
  25. Secondary prevention of acute coronary syndrome with antiplatelet agents in real life: A high-dimensional propensity score matched cohort study in the French National claims database.
    Blin P, Dureau-Pournin C, Jové J, Lassalle R, Droz C, Moore N.
    MethodsX. 2020
  26. [Management of mild asthma in 2019-2020: What about new international therapeutic proposals (GINA 2019)?]
    Raherison C, Deschildre A, Garcia G, Girodet PO, Taillé C, Chenivesse C, Devouassoux G, Molimard M, Didier A.
    Rev Mal Respir. 2020
  27. DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database.
    Gouverneur A, Lair A, Arnaud M, Bégaud B, Raschi E, Pariente A, Salvo F.
    Lancet Diabetes Endocrinol. 2020
  28. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic.
    Pottegård A, Kurz X, Moore N, Christiansen CF, Klungel O.
    Pharmacoepidemiol Drug Saf. 2020
  29. Impact of pregnancy on antidepressant treatment course: a population-based comparative cohort study in France.
    Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Pariente A.
    Arch Womens Ment Health. 2020
  30. Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic.
    Larrouquere L, Gabin M, Poingt E, Mouffak A, Hlavaty A, Lepelley M, Khouri C, Bellier A, Alexandre J, Bedouch P, Bertoletti L, Bordet R, Bouhanick B, Jonville-Bera AP, Laporte S, Le Jeunne C, Letinier L, Micallef J, Naudet F, Roustit M, Molimard M, Richard V, Cracowski JL; Société Française de Pharmacologie et de Thérapeutique, Hôpital Bretonneau, Tours, France.
    Fundam Clin Pharmacol. 2020
  31. Use of benzodiazepines non-compliant with guidelines in patients with psychiatric and non-psychiatric chronic disorders.
    Panes A, Verdoux H, Fourrier-Réglat A, Berdaï D, Pariente A, Tournier M.
    Gen Hosp Psychiatry. 2020
  32. COVID-19 infection also occurs in patients taking hydroxychloroquine.
    Lahouati M, Mériglier E, Martin L, Bouchet S, Desclaux A, Bonnet F.
    J Antimicrob Chemother. 2020
  33. Susceptibility to frequent exacerbation in COPD patients: Impact of the exacerbations history, vaccinations and comorbidities?
    Ouaalaya EH, Falque L, Dupis JM, Sabatini M, Bernady A, Nguyen L, Ozier A, Nocent-Ejnaini C, Le Guillou F, Molimard M, Zysman M, Raherison-Semjen C.
    Respir Med. 2020
  34. Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis.
    Bui S, Facchin A, Ha P, Bouchet S, Leroux S, Nacka F, Fayon M, Jacqz-Aigrain E; network of Paediatric Clinical Investigation Centres.
    J Antimicrob Chemother. 2020
  35. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.
    Roustit M, Guilhaumou R, Molimard M, Drici MD, Laporte S, Montastruc JL; French Society of Pharmacology and Therapeutics (SFPT).
    Therapie. 2020
  36. Ten-year trend of opioid and non-opioid analgesic use in the French adult population.
    Daveluy A, Micallef J, Sanchez-Pena P, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Corand V, Victorri-Vigneau C, Batisse A, Le Boisselier R, Peyrière H, Frauger E, Lapeyre-Mestre M, Haramburu F; French Addictovigilance Network.
    Br J Clin Pharmacol. 2020
  37. [Research ethics: French regulations and applications in radiation oncology]
    Haaser T, Berdaï D, Trouette R, Dupin C, Marty S, L'Azou B, Berger V, Saux MC.
    Cancer Radiother. 2020
  38. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.
    Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G.
    Orphanet J Rare Dis. 2020
  39. Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS).
    Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz-Perroteau C.
    Pharmacoepidemiol Drug Saf. 2020
  40. Does Ibuprofen Worsen COVID-19?
    Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C.
    Drug Saf. 2020
  41. Factors associated with serious vehicular accidents: a cross-sectional study in hospital emergency rooms.
    Forest K, Valdenaire G, Lorendeau JP, Sagaspe P, Contrand B, Durand-Teyssier C, Sakr D, Gil-Jardine C, Boutreux S, Lagarde E, Peyrouzet H, Lassalle R, Moore N, Philip P, Girodet PO.
    Br J Clin Pharmacol. 2020
  42. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.
    Cracowski JL, Molimard M, Richard V.
    Therapie. 2020
  43. Patterns of use and safety of ibrutinib in real-life practice.
    Allouchery M, Tomowiak C, Guidez S, Delwail V, Delaunay P, Lafay-Chebassier C, Salvo F, Pérault-Pochat MC.
    Br J Clin Pharmacol. 2020
  44. Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study.
    Suehs CM, Zysman M, Chenivesse C, Burgel PR, Couturaud F, Deslee G, Berger P, Raherison C, Devouassoux G, Brousse C, Roche N, Molimard M, Chinet T, Devillier P, Chanez P, Kessler R, Didier A, Martinat Y, Le Rouzic O, Bourdin A.
    BMJ Open. 2020
  45. Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort .
    Rouyer M, Francois E, Sa Cunha A, Monnereau A, Bignon E, Jove J, Lassalle R, Droz-Perroteau C, Moore N, Noize P, Fourrier-Réglat A, Smith D.
    Br J Clin Pharmacol. 2020
  46. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
    Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C; ANRS-AC43 Clinical Pharmacology Committee, SFPT Therapeutic Drug Monitoring and Treatment Personalization group.
    Antiviral Res. 2020
  47. Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
    Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, Peyrière H, Micallef J; French Addictovigilance Network.
    Therapie. 2020
  48. Impact of Secured Prescription Implementation for Zolpidem on Hypnotics Use in France: A Time-Series Analysis on National Data.
    Rousselot N, Pariente A, Mansiaux Y, Victorri-Vigneau C.
    Ann Fam Med. 2020
  49. Risk of bradyarrhythmia related to ticagrelor: a systematic review and meta-analysis.
    Pujade I, Perino J, Mathieu C, Arnaud M, Raschi E, Gatti M, Bezin J, Salvo F.
    Pharmacol Res. 2020
  50. Reprint of: The effect of the Music Day event on community drug use.
    Devault DA, Peyré A, Jaupitre O, Daveluy A, Karolak S.
    Forensic Sci Int. 2020
  51. Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.
    Gorwood P, Benichou J, Moore N, Wattez M, Secouard MC, Desobry X, Picarel-Blanchot F, de Bodinat C.
    Clin Drug Investig. 2020
  52. Antidopaminergic antiemetics and trauma-related hospitalization: a population-based self-controlled case series study.
    Bezin J, Noize P, Mansiaux Y, Jarne A, Pariente A.
    Br J Clin Pharmacol. 2020
  53. Overview of French databases available for studying anticancer drugs in real life setting.
    Casarotto E, Noize P, Gouverneur A, Berdaï D, Bégaud B, Levy-Bachelot L, Molimard M.
    Fundam Clin Pharmacol. 2020
  54. Association between anxiolytic/hypnotic drugs and suicidal thoughts or behaviors in a population-based cohort of students.
    Lecat N, Fourrier-Réglat A, Montagni I, Tzourio C, Pariente A, Verdoux H, Tournier M.
    Psychiatry Res. 2020
  55. Treatment resistant depression incidence and prevalence using the French nationwide claims database.
    Bosco-Lévy P, Grelaud A, Blin P, Astruc B, Falissard B, Llorca PM, Bernard MA, Lassalle R, Moore N, Droz-Perroteau C.
    Pharmacoepidemiol Drug Saf. 2020
  56. No arguments for extra risk from ibuprofen in SARS-COV2 infection.
    Moore N.
    Therapie. 2020
  57. Health consequences of cocaine use in France: data from the French addictovigilance network.
    Eiden C, Vincent M, Serrand C, Serre A, Richard N, Picot MC, Frauger E, Fouilhé N, Daveluy A, Peyrière H; French Addictovigilance Network (FAN).
    Fundam Clin Pharmacol. 2020
  58. [Use of synthetic substances in France and in Europe]
    Debruyne D, Monzon E, Perino J, Haramburu F, Daveluy A, Lazès-Charmetant A, Giraudon I.
    Therapie. 2020
  59. Impact of benzodiazepine consumption reduction on future burden of dementia.
    Jacqmin-Gadda H, Guillet F, Mathieu C, Helmer C, Pariente A, Joly P.
    Sci Rep. 2020
  60. Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.
    Arlegui H, Bollaerts K, Salvo F, Bauchau V, Nachbaur G, Bégaud B, Praet N.
    Drug Saf. 2020
  61. Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).
    Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, Bégaud B, Praet N.
    Drug Saf. 2020
  62. The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.
    Gorwood P, Benichou J, Moore N, Álvarez Martínez E, Mertens J, Aguglia E, Figueira ML, Falkai P, Olivier V, Wattez M, Picarel-Blanchot F, de Bodinat C.
    Hum Psychopharmacol. 2020
  63. A highly sensitive UHPLC-MS/MS method for urine biological monitoring of occupational exposure to anthracycline antineoplastic drugs and routine application.
    Villa A, Tremolet K, Martinez B, Da Silva Cacao O, Atgé B, Ducint D, Titier-Debeaupuis K, Verdun-Esquer C, Molimard M, Canal-Raffin M.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2020
  64. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France.
    Arlegui H, Nachbaur G, Praet N, Bégaud B, Caro JJ.
    Clin Ther. 2020
  65. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R, Journot V, Nguyen D, Peiffer-Smadja N, Crémer A, Bouchet S, Darnaud T, Poitrenaud D, Piroth L, Binquet C, Michel JF, Lefèvre B, Lebeaux D, Lebel J, Dupouy J, Roussillon C, Gimbert A, Wittkop L, Thiébaut R, Orne-Gliemann J, Joseph JP, Richert L, Anglaret X, Malvy D; COVERAGE study group.
    Trials. 2020
  66. [Therapeutic education, compliance and self-medication]
    Rosellini P, Berdaï D, Molimard M, Girodet PO.
    Rev Prat. 2020
  67. Suitability of infrared spectroscopy for drug checking in harm reduction centres.
    Goncalves R, Titier K, Latour V, Peyré A, Castaing N, Daveluy A, Molimard M.
    Int J Drug Policy. 2020
  68. The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy .
    Guillot J, Maumus-Robert S, Marceron A, Noize P, Pariente A, Bezin J.
    J Clin Med. 2020
  69. Safety Profile of Drugs for Advanced Melanoma: A Report Based on 2008 to 2018 United States Food and Drug Administration Data.
    Casarotto E, Noize P, Létinier L, Salvo F, Pham-Ledard A, Molimard M.
    Br J Clin Pharmacol. 2020
  70. Medicine misuse: A systematic review and proposed hierarchical terminology.
    Singier A, Noize P, Berdaï D, Daveluy A, Arnaud M, Molimard M, Bégaud B, Salvo F.
    Br J Clin Pharmacol. 2020
  71. The determinants of dyspnoea evaluated by the mMRC scale: The French Palomb cohort.
    Ouaalaya EH, Falque L, Dupis JM, Sabatini M, Bernady A, Nguyen L, Ozier A, Nocent-Ejnaini C, Le Guillou F, Molimard M, Raherison-Semjen C.
    Respir Med Res. 2020
  72. Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database.
    Blin P, Rouyer M, Guiard E, Zerbib F, Diquet B, Mégraud F, Tison F, Abouelfath A, Lassalle R, Droz-Perroteau C, Moore N.
    Therapie. 2020
  73. [Substance use among young people: From medicine to illicit substances]
    Lapeyre-Mestre M, Boyer A, Ponté C, Daveluy A, Godeau E.
    Therapie. 2020
  74. A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis.
    Woillard JB, Bouchet S, Fayon M, Marquet P, Monchaud C, Bui S.
    Ther Drug Monit. 2020
  75. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers.
    J Immunother Cancer. 2020